Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8828427 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Jun, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6476052 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Jul, 2016
(7 years ago) | |
US5653517 | BRISTOL | Process and system for determination of friction/slip characteristics of road vehicle tires |
Jul, 2016
(7 years ago) | |
US5635517 | BRISTOL | Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines |
Jul, 2016
(7 years ago) | |
US8158653 | BRISTOL | Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline |
Aug, 2016
(7 years ago) | |
US6316471 | BRISTOL | Isoindolines, method of use, and pharmaceutical compositions |
Aug, 2016
(7 years ago) | |
US8589188 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6561976 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6908432 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US8204763 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6045501 | BRISTOL | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug, 2018
(5 years ago) | |
US6561977 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6315720 | BRISTOL | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct, 2020
(3 years ago) | |
US8626531 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US8315886 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US6755784 | BRISTOL | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct, 2020
(3 years ago) | |
US8735428 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(11 months ago) | |
US8673939 | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
May, 2023
(11 months ago) | |
US8673939 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(5 months ago) | |
US8735428 (Pediatric) | BRISTOL | Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Nov, 2023
(5 months ago) | |
US8198262 | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Jun, 2025
(1 year, 1 month from now) | |
US8198262 (Pediatric) | BRISTOL | Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione |
Dec, 2025
(1 year, 7 months from now) | |
US9993467 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
US10555939 | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
May, 2030
(6 years from now) | |
US9993467 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
US10555939 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Nov, 2030
(6 years from now) | |
US8828427 (Pediatric) | BRISTOL | Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
Dec, 2031
(7 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M(M-14) | Nov 20, 2023 |
Orphan Drug Exclusivity(ODE-297) | May 14, 2027 |
Orphan Drug Exclusivity(ODE-296) | May 14, 2027 |
Pediatric Exclusivity(PED) | Nov 14, 2027 |
New Indication(I-707) | Apr 23, 2018 |
Orphan Drug Exclusivity(ODE-43) | Feb 08, 2020 |
Orphan Drug Exclusivity(ODE) | Feb 08, 2020 |
New Chemical Entity Exclusivity(NCE) | Feb 08, 2018 |
NCE-1 date: 14 November, 2026
Market Authorisation Date: 08 February, 2013
Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha; Use of pomalidomide while ...
Dosage: CAPSULE;ORAL